Amyotrophic lateral sclerosis: A review of current concepts

References

• Charcot J, Joffroy A. Deux cas d’atrophie musculaire progressive avec lesions de la substance grise et des faisceaux anterolateraux de la moelle epiniere. Arch Physiol Norm Pathol 1869; 2: 354–744.
   Google Scholar
• Charcot J. De la sclerose laterale amytrophique. Prog. Med. 1874; 2: 325–327, 341–342, 453–455.
   Google Scholar
• World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial Revisited: Revised Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis, ALS Consensus Conference, Airlie House, Warrington, Virginia, 1998. Vol. www.wfnals.org. World Federation of Neurology.
   Google Scholar
• Kleopa KA, Sherman M, Neal B et al. Bipap improves survival and rate of pulmonary function decline in patients with ALS [see comments]. Journal of the Neurological Sciences 1999; 164: 82–88.
   Google Scholar
• Mazzini L, Corra T, Zaccala M et al. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. Journal of Neurology 1995; 242: 695–698.
   Google Scholar
• Chou S. Neuropathology of amyotrophic lateral sclerosis: new perspectives on an old disease. J Formos Med Assoc 1997; 96: 488–498.
   PubMed Web of Science ®Google Scholar
• Massman PJ, Sims J, Cooke N et al. Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 1996; 61: 450–455.
   Google Scholar
• Strong MJ, Grace GM, Orange JB et al. A prospective study of cognitive impairment in ALS. Neurology 1999; 53: 1665– 1670.
   PubMed Web of Science ®Google Scholar
• Wilson CM, Grace GM, Munoz DG et al. Cognitive impairment in sporadic ALS: a pathologic continuum underlying a multi- system disorder. Neurology 2001; 57: 651–657.
   Google Scholar
• Hudson AJ, Davenport A, Hader WJ. The incidence of amyotrophic lateral sclerosis in southwestern Ontario, Canada. Neurology 1986; 36: 1524–1528.
   PubMed Web of Science ®Google Scholar
• Riggs JE. Longitudinal Gompertzian analysis of amyotrophic lateral sclerosis mortality in the U.S., 1977–1986: evidence for an inherently susceptible population subset. Mechanisms of Ageing & Development 1990; 55: 207–220.
   PubMed Web of Science ®Google Scholar
• Lilienfeld AM, Jacobs M, Willis M. A study of reproducibility of muscle testing and certain other aspects of muscle scoring. Physical Therapy Rev 1954; 34: 279.
   Google Scholar
• Durrleman S, Alperovitch A. Increasing trend of ALS in France and elsewhere: are the changes real? Neurology 1989; 39: 768–773.
   PubMed Web of Science ®Google Scholar
• Provinciali L, Giovagnoli AR. Antecedent events in amyotrophic lateral sclerosis: do they influence clinical onset and progression? Neuroepidemiology 1990; 9: 255–262.
   PubMed Web of Science ®Google Scholar
• Garruto RM. Pacific paradigms of environmentally-induced neurological disorders: clinical, epidemiological and molecular perspectives. Neurotoxicology 1991; 12: 347–377.
   PubMed Web of Science ®Google Scholar
• Garruto RM, Yanagihara R, Gajdusek DC. Disappearance of high-incidence amyotrophic lateral sclerosis and Parkinsonism- dementia on Guam. Neurology 1985; 35: 193–198.
   PubMed Web of Science ®Google Scholar
• Plato CC, Garruto RM, Fox KM, Gajdusek DC. Amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam: a 25-year prospective case-control study. American Journal of Epidemiology 1986; 124: 643–656.
   PubMed Web of Science ®Google Scholar
• Granieri E, Carreras M, Tola R et al. Motor neuron disease in the province of Ferrara, Italy, in 1964–1982. Neurology 1988; 38: 1604–1608.
   Google Scholar
• Rosati G, Pinna L, Granieri E et al. Studies on epidemiological, clinical, and etiological aspects of ALS disease in Sardinia, Southern Italy. Acta Neurologica Scandinavica 1977; 55: 231–244.
   Google Scholar
• Giagheddu M, Puggioni G, Biancu F et al. Epidemiological study of amyotrophic lateral sclerosis in Sardinia, Italy. Acta Neurol. Scand. 1983; 68: 394–404.
   Google Scholar
• Bracco L, Antuono P, Amaducci L. Study of epidemiological and etiological factors of amyotrophic lateral sclerosis in the province of Florence, Italy. Acta Neurologica Scandinavica 1979; 60: 112–124.
   PubMed Web of Science ®Google Scholar
• Gunnarsson L, Palm R. Motor neuron disease and heavy manual labor: an epidemiological survey of Varmland County, Sweden. Neuroepidemiology 1984; 3: 195–206.
   Google Scholar
• Felmus MT, Patten BM, Swanke L. Antecedent events in amyotrophic lateral sclerosis. Neurology 1976; 26: 167– 172.
   PubMed Web of Science ®Google Scholar
• Hawkes CH, Cavanagh JB, Fox AJ. Motoneuron disease: a disorder secondary to solvent exposure? Lancet 1989; 1: 73–76.
   PubMed Web of Science ®Google Scholar
• Strickland D, Smith SA, Dolliff G et al. Amyotrophic lateral sclerosis and occupational history. A pilot case-control study. Archives of Neurology 1996; 53: 730–733.
   Google Scholar
• Abarbanel JM, Herishanu Y, Frisher S. Motor neuron disease in textile factory workers. Israel Journal of Medical Sciences 1985; 21: 924–925.
   PubMedGoogle Scholar
• Cruz D, Nelson L, McGuire V, Longstreth WJ. Physical trauma and family history of neurodegenerative diseases in amyotrophic lateral sclerosis: a population-based case-control study. Neuroepidemiology 1999; 18: 101–110.
   PubMed Web of Science ®Google Scholar
• Gallagher J, Sanders M. Trauma and amyotrophic lateral sclerosis: a report of 78 patients. Acta Neurologica Scandinavica 1987; 75: 145–150.
   PubMed Web of Science ®Google Scholar
• Riggs J. Antecedent trauma and amyotrophic lateral sclerosis in young adult men. Military Medicine 1993; 158: 55–57.
   PubMed Web of Science ®Google Scholar
• Riggs J. Trauma, axonal injury, and amyotrophic lateral sclerosis: a clinical correlate of a neuropharmacologic model. Clinical Neuropharmacology 1995; 18: 273–276.
   PubMed Web of Science ®Google Scholar
• McGuire V, Longstreth WT., Jr., Nelson LM et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. American Journal of Epidemiology 1997; 145: 1076–1088.
   Google Scholar
• Strong M. Exogenous neurotoxins. In Brown RD, Jr., Meininger V. & Swash M, in (eds). Amyotrophic lateral sclerosis, Martin Dunitz Limited, London, 2000;279–287.
   Google Scholar
• Nelson LM, McGuire V, Longstreth WT, Jr., Matkin C. Popula- tion-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. American Journal of Epidemiology 2000; 151: 156–163.
   Google Scholar
• Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis [see comments]. Muscle & Nerve 1989; 12: 833–841.
   PubMed Web of Science ®Google Scholar
• Eisen A, Schulzer M, MacNeil M et al. Duration of amyotrophic lateral sclerosis is age dependent. Muscle & Nerve 1993; 16: 27–32.
   Google Scholar
• Strong MJ, Hudson AJ, Alvord WG. Familial amyotrophic lateral sclerosis, 1850–1989: a statistical analysis of the world literature. Canadian Journal of Neurological Sciences 1991; 18: 45–58.
   PubMed Web of Science ®Google Scholar
• Cashman N, Cudkowicz M, Davidson M et al. Database APC. Gender effects on duration and onset age of amyotrophic lateral sclerosis. ALS and other motor neuron disorders 2. 2001: 41–42.
   Google Scholar
• Brooks BR. El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Journal of Neurological Sciences 1994; 124(Suppl): 96–107.
   Google Scholar
• Ross MA, Miller RG, Berchert L et al. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group. Neurology 1998; 50: 768–772.
   Google Scholar
• Strong MJ. Simplifying the approach: what can we do? Neurology 1999; 53: S31–4; discussion S35–6.
   Google Scholar
• Fujita K, Honda M, Hayashi R et al. Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: a possible use as an indicator of extent of the motor neuron loss. Journal of the Neurological Sciences 1998; 158: 53–57.
   Google Scholar
• Heafield MT, Fearn S, Steventon GB et al. Plasma cysteine and sulphate levels in patients with motor neuron, Parkinson’s and Alzheimer’s disease. Neuroscience Letters 1990; 110: 216–220.
   Google Scholar
• Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurologica Scandinavica 1993; 88: 51–55.
   PubMed Web of Science ®Google Scholar
• Tumani H, Shen G, Peter JB, Bruck W. Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer’s disease? Archives of Neurology 1999; 56: 1241–1246.
   PubMedGoogle Scholar
• Stevens A, Weller M, Wietholter H. A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 1993; 56: 361–364.
   PubMed Web of Science ®Google Scholar
• Younger DS, Rowland LP, Latov N et al. Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology 1990; 40: 595–599.
   Google Scholar
• Norris FH, Burns W, U KS, Mukai E, Norris H. Spinal fluid cells and protein in amyotrophic lateral sclerosis. Archives of Neurology 1993; 50: 489–491.
   Google Scholar
• Bogdanov M, Brown RH, Matson W et al. Increased oxidative damage to DNA in ALS patients. Free Radical Biology & Medicine 2000; 29: 652–658.
   PubMed Web of Science ®Google Scholar
• Beal MF, Ferrante RJ, Browne SE et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis [see comments]. Comment in: Ann Neurol 1999 Mar;45(3):413–414. Annals of Neurology 1997; 42: 644–654.
   Google Scholar
• Tohgi H, Abe T, Yamazaki K et al. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Annals of Neurology 1999; 46: 129–131.
   Google Scholar
• Tohgi H, Abe T, Yamazaki K et al. Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neuroscience Letters 1999; 260: 204–206.
   Google Scholar
• Hlzecka J, Stelmasiak Z, Dobosz B. Interleukin-1beta converting enzyme/Caspase-1 (ICE/Caspase-1) and soluble APO-1/Fas/CD 95 receptor in amyotrophic lateral sclerosis patients. Acta Neurologica Scandinavica 2001; 103: 255–258.
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Karlsson JE, Karlsson JO et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. Journal of Neurochemistry 1996; 67: 2013–2018.
   Google Scholar
• Pestronk A, Adams RN, Clawson L et al. Serum antibodies to Gm1 Ganglioside In Amyotrophic Lateral Sclerosis. Neurology 1988; 38: 1457–1461.
   Google Scholar
• Lamb NL, Patten BM. Clinical correlations of anti-GM1 antibodies in amyotrophic lateral sclerosis and neuropathies. Muscle & Nerve 1991; 14: 1021–1027.
   PubMed Web of Science ®Google Scholar
• Sanders KA, Rowland LP, Murphy PL et al. Motor neuron diseases and amyotrophic lateral sclerosis: GM1 antibodies and paraproteinemia. Neurology 1993; 43: 418–420.
   Google Scholar
• Fullmer H, Siedler H, Krooth R, Kurland L. A cutaneous disorder of connective tissue in amyotrophic lateral sclerosis. A histo- chemical study. Neurology 1960; 10: 717–724.
   PubMed Web of Science ®Google Scholar
• Ono S, Imai T, Takahashi K et al. Increased type III procollagen in serum and skin of patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica 1999; 100: 377–384.
   Google Scholar
• Ono S, Imai T, Shimizu N, Nagao K. Increased expression of laminin 1 in the skin of amyotrophic lateral sclerosis. European Neurology 2000; 43: 215–220.
   PubMed Web of Science ®Google Scholar
• Ono S, Imai T, Takahashi K et al. Decreased type IV collagen of skin and serum in patients with amyotropic lateral sclerosis. Neurology 1998; 51: 114–120.
   Google Scholar
• Ono S, Shimizu N, Imai T et al. Increased cystatin C immunoreactivity in the skin in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica 2000; 102: 47–52.
   Google Scholar
• Poloni M, Capitani E, Mazzini L, Ceroni M. Neuropsychological measures in amyotrophic lateral sclerosis and their relationship with CT scan-assessed cerebral atrophy. Acta Neurologica Scandinavica 1986; 74: 257–260.
   PubMed Web of Science ®Google Scholar
• Kew JJ, Goldstein LH, Leigh PN et al. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain 1993; 116: 1399–1423.
   Google Scholar
• Gallassi R, Montagna P, Morreale A et al. Neuropsychological, electroencephalogram and brain computed tomography findings in motor neuron disease. European Neurology 1989; 29: 115– 120.
   Google Scholar
• Ludolph AC, Elger CE, Bottger IW et al. N-isopropyl-p-123I- amphetamine single photon emission computer tomography in motor neuron disease. European Neurology 29: 255– 260.
   Google Scholar
• Waldemar G, Vorstrup S, Jensen TS et al. Focal reductions of cerebral blood flow in amyotrophic lateral sclerosis: a [99mTc]- d,l-HMPAO SPECT study. Journal of the Neurological Sciences 1992; 107: 19–28.
   Google Scholar
• Talbot PR, Goulding PJ, Lloyd JJ et al. Inter-relation between classic motor neuron disease and frontotemporal dementia: neuropsychological and single photon emission computed tomography study. Journal of Neurology, Neurosur- gery & Psychiatry 1995; 58: 541–547.
   Google Scholar
• Tanaka M, Kondo S, Hirai S et al. Cerebral blood flow and oxygen metabolism in progressive dementia associated with amyotrophic lateral sclerosis. Journal of the Neurological Sciences 1993; 120: 22–28.
   Google Scholar
• Ludolph AC, Langen KJ, Regard M et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurologica Scandinavica 1992; 85: 81–89.
   Google Scholar
• Abrahams S, Goldstein LH, Lloyd CM et al. Cognitive deficits in non-demented amyotrophic lateral sclerosis patients: a neuro- psychological investigation. Journal of the Neurological Sciences 1995; 129: 54–55.
   Google Scholar
• Abrahams S, Leigh PN, Kew JJ et al. A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. Journal of the Neurological Sciences 1995; 129: 44–46.
   Google Scholar
• Strong MJ, Grace GM, Orange JB, Leeper HA. Cognition, language, and speech in amyotrophic lateral sclerosis: a review. Journal of Clinical & Experimental Neuropsychology 1996; 18: 291–303.
   PubMed Web of Science ®Google Scholar
• Strong M. The evidence for ALS as a multisystems disorder of limited phenotypic expression. Can J Neurol Sci 2001; 28: 283–298.
   PubMed Web of Science ®Google Scholar
• Julien JP. Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell 2001; 104: 581–591.
   PubMed Web of Science ®Google Scholar